EverSource Wealth Advisors LLC Reduces Position in CRISPR Therapeutics AG $CRSP

Posted by Francis Steltz on May 24th, 2026

EverSource Wealth Advisors LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 41.0% during the fourth quarter, Holdings Channel reports. The fund owned 57,465 shares of the company’s stock after selling 39,969 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in CRISPR Therapeutics were worth $3,013,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of CRSP. Orbis Allan Gray Ltd increased its position in shares of CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock worth $134,467,000 after acquiring an additional 1,201,600 shares during the last quarter. SR One Capital Management LP increased its position in shares of CRISPR Therapeutics by 94.4% during the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock worth $132,132,000 after acquiring an additional 989,812 shares during the last quarter. State Street Corp increased its position in shares of CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after acquiring an additional 859,334 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of CRISPR Therapeutics by 98.3% during the third quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock worth $38,459,000 after acquiring an additional 294,222 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of CRISPR Therapeutics by 2,346.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,305 shares of the company’s stock worth $12,077,000 after acquiring an additional 220,892 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Stock Up 0.9%

NASDAQ:CRSP opened at $50.36 on Friday. The company has a market capitalization of $4.86 billion, a price-to-earnings ratio of -8.10 and a beta of 1.74. CRISPR Therapeutics AG has a one year low of $35.38 and a one year high of $78.48. The stock has a 50-day simple moving average of $50.88 and a 200 day simple moving average of $53.26. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. Sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 10,349 shares of CRISPR Therapeutics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $499,442.74. Following the completion of the transaction, the chief executive officer directly owned 245,834 shares in the company, valued at approximately $11,863,948.84. This trade represents a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Naimish Patel sold 3,150 shares of CRISPR Therapeutics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the transaction, the insider owned 13,143 shares of the company’s stock, valued at $634,281.18. This trade represents a 19.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 42,749 shares of company stock worth $2,100,723. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CRSP. Needham & Company LLC lifted their target price on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Evercore reaffirmed an “outperform” rating and set a $76.00 target price on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Truist Financial raised CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Chardan Capital lifted their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a research report on Saturday, February 14th. Finally, TD Cowen lifted their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.47.

Check Out Our Latest Stock Analysis on CRISPR Therapeutics

About CRISPR Therapeutics

(Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.